PathAI, a leader in artificial intelligence and digital pathology solutions, has unveiled MET Predict, a groundbreaking AI-powered algorithm integrated into their AISightⓇ Image management system. This new tool is poised to revolutionize the assessment of non-small cell lung cancer (NSCLC) tumors by helping pathologists identify cases that may be more likely to have MET exon 14 skipping (METex14) or MET amplification from H&E whole slide images.
NSCLC represents approximately 85% of lung cancer cases, with 3-4% involving METex14 mutations. Currently, targeted therapies are available for NSCLC patients with METex14 mutations, and MET amplification, occurring in 1-6% of NSCLC cases, is emerging as a potential biomarker. However, traditional molecular testing for these alterations faces challenges such as high costs, time-consuming procedures, and the need for specialized equipment and personnel, limiting its accessibility and scalability.
MET Predict addresses these challenges by offering a more efficient and cost-effective method to assess MET alterations. The algorithm boasts an impressive capability to identify over 90% of MET altered tumors while potentially preserving tissue in 30% of cases where the likelihood of MET alteration is low. This advancement could significantly streamline the biomarker evaluation process and improve molecular testing paradigms.
Dr. Andy Beck, co-founder and CEO of PathAI, emphasized the significance of this development, stating, ‘The integration of MET Predict into AISight marks a significant leap forward in utilizing AI to enhance the efficiency of NSCLC tumor assessments, particularly in identifying those with potential genetic alterations.’ He added that the tool provides rapid and precise biomarker insights directly from H&E images, equipping pathologists with essential information for timely and accurate NSCLC evaluations.
The introduction of MET Predict expands AISight’s toolset, addressing a crucial gap in pathology labs – the need for accessible, rapid, and comprehensive molecular tools that provide actionable insights from biopsy samples. This innovation could potentially reduce the time and resources required for cancer diagnostics while improving the accuracy of assessments.
It’s important to note that MET Predict and AISight are currently for Research Use Only and not for use in diagnostic procedures. However, their potential impact on the field of pathology and cancer diagnostics is significant. By leveraging AI technology, these tools could democratize access to advanced molecular insights, potentially leading to more personalized treatment strategies for lung cancer patients.
The launch of MET Predict aligns with the growing trend of AI integration in healthcare, particularly in the realm of cancer diagnostics. As the field continues to evolve, tools like MET Predict may play a crucial role in enhancing the accuracy and efficiency of cancer assessments, ultimately contributing to improved patient outcomes.
For the medical community, particularly oncologists and pathologists, the introduction of MET Predict represents a valuable addition to their diagnostic toolkit. It offers the potential to streamline workflows, reduce turnaround times for biomarker evaluations, and potentially identify more patients who could benefit from targeted therapies.
As PathAI continues to innovate in the field of AI-powered pathology solutions, the launch of MET Predict marks a significant step forward in the company’s mission to transform diagnostic accuracy and operational efficiency in pathology labs worldwide. The potential of this technology to impact patient care and advance the field of precision medicine in oncology is substantial, making it a development worth watching in the coming years.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is PathAI Introduces AI-Powered Tool to Enhance Lung Cancer Assessments.